Compare AQST & TRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AQST | TRTX |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.4M | 471.4M |
| IPO Year | 2007 | 2015 |
| Metric | AQST | TRTX |
|---|---|---|
| Price | $4.63 | $5.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $9.33 | ★ $9.88 |
| AVG Volume (30 Days) | ★ 2.1M | 978.0K |
| Earning Date | 11-04-2026 | 10-27-2026 |
| Dividend Yield | N/A | ★ 15.87% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.19 |
| Revenue | ★ $67,430,000.00 | N/A |
| Revenue This Year | $12.09 | N/A |
| Revenue Next Year | $35.73 | $8.53 |
| P/E Ratio | ★ N/A | $31.84 |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $2.94 | $6.02 |
| 52 Week High | $7.55 | $9.37 |
| Indicator | AQST | TRTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.09 | 12.47 |
| Support Level | $4.51 | N/A |
| Resistance Level | $4.69 | $8.74 |
| Average True Range (ATR) | 0.22 | 0.19 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 28.36 | 6.03 |
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.